Cipher Pharmaceuticals Appoints Norm Evans Chief Financial Officer



    Toronto Stock Exchange Symbol: DND

    MISSISSAUGA, ON, March 8 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND)
today announced that Norman C. Evans, CA, has been appointed Chief Financial
Officer of the Company, effective March 8, 2007. He replaces Acting Chief
Financial Officer Tom Hudson. Mr. Hudson will provide support to ensure a
smooth transition of responsibilities, while continuing in his capacity as
Corporate Controller at CML Healthcare Inc.
    "Norm's senior-level experience in the life sciences industry and broad
skill set will make him a valuable addition to Cipher as we build the Company
and execute our growth strategy," said Larry Andrews, President and CEO of
Cipher. "In addition to the financial management of Cipher, Norm will play an
important role in strategic planning, capital markets activities, and business
development. On behalf of the management team and board, I would also like to
thank Tom for his significant contributions to Cipher over the past year."
    Mr. Evans was most recently Vice-President, Finance for the Early Stage
Development division of MDS Inc. (MDS), Canada's leading health and life
sciences company. Previously, Mr. Evans served as Vice-President, Finance for
MDS Pharma Services, the largest division of MDS, with annual revenue or more
than $500 million. In this role, he had responsibility for the financial
management of the division, including reporting, forecasting and long-term
strategic planning. As part of the senior management team, he was involved in
setting strategic direction, identifying acquisition targets and completing
acquisitions. Prior to joining MDS, Mr. Evans spent 19 years at Ernst & Young
where he held the position of Partner in the Toronto office.
    Mr. Evans is a Chartered Accountant. He also holds a Bachelor of Science
degree from Concordia University in Montreal.

    About Cipher Pharmaceuticals Inc.
    Cipher Pharmaceuticals is a drug development company focused on
commercializing novel formulations of successful, currently marketed molecules
using advanced drug delivery technologies. Cipher's strategy is to in-license
products that incorporate proven drug delivery technologies and advance them
through the clinical development and regulatory approval stages, after which
the products are out-licensed to international partners. Because Cipher's
products are based on proven technology platforms applied to currently
marketed drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. Cipher
currently has three late-stage drugs in its pipeline. The Company's lead
compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug
Administration and Health Canada in the first quarter of 2006. In addition,
Cipher is developing formulations of the pain reliever tramadol (currently
under regulatory review by the FDA) and the acne treatment isotretinoin
(currently under regulatory review by the FDA).
    Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and
has approximately 24 million shares outstanding. For more information, please
visit www.cipherpharma.com.

    Forward-Looking Statements

    Statements made in this news release, other than those concerning
historical financial information, may be forward-looking and therefore subject
to various risks and uncertainties. Some forward-looking statements may be
identified by words like "may", "will", "anticipate", "estimate", "expect",
"intend", or "continue" or the negative thereof or similar variations. Certain
material factors or assumptions are applied in making forward-looking
statements and actual results may differ materially from those expressed or
implied in such statements. Factors that could cause results to vary include
those identified in the Company's Annual Information Form and other filings
with Canadian securities regulatory authorities, such as the applicability of
patents and proprietary technology; possible patent litigation; regulatory
approval of products in the Company's pipeline; changes in government
regulation or regulatory approval processes; government and third-party payer
reimbursement; dependence on strategic partnerships for product candidates and
technologies, marketing and R&D services; meeting projected drug development
timelines and goals; intensifying competition; rapid technological change in
the pharmaceutical industry; anticipated future losses; the ability to access
capital to fund R&D; and the ability to attract and retain key personnel. All
forward-looking statements presented herein should be considered in
conjunction with such filings. The Company does not undertake to update any
forward-looking statements; such statements speak only as of the date made.

    %SEDAR: 00020415E




For further information:

For further information: Craig Armitage, Investor Relations, The Equicom
Group, (416) 815-0700 ext 278, (416) 815-0080 fax, carmitage@equicomgroup.com;
Larry Andrews, President & Chief Executive Officer, Cipher Pharmaceuticals,
(905) 602-5840 ext 24, (905) 602-0628 fax, landrews@cipherpharma.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890